Business Summary
Alpha Cognition Inc. (ACOG) is a small-cap biopharmaceutical company headquartered in Vancouver, BC (with U.S. operations in Dallas/Fort Worth, TX) focused exclusively on treatments for neurodegenerative diseases — primarily Alzheimer's disease. The company's central milestone is the FDA approval of ZUNVEYL (benzgalantamine) in July 2024 and its commercial launch in March 2025. With 71 full-time employees, Alpha Cognition is transitioning from a clinical-stage company to a commercial-stage specialty pharma with a pre-revenue base and a targeted long-term care (LTC) go-to-market strategy.
Products & Services
Commercial Product: - ZUNVEYL (benzgalantamine) — delayed-release oral tablet (5 mg, 10 mg, 15 mg), FDA-approved July 2024, launched March 2025. A next-generation acetylcholinesterase inhibitor (AChEI) with dual mechanism of action (AChE inhibition + nicotinic receptor modulation, notably alpha-7 subtype). Enteric-coated to minimize gastrointestinal side effects. Indicated for mild-to-moderate Alzheimer's disease in adults. WAC set at $820/month.
Pipeline (Pre-Clinical): - **ZUNVEYL +...
AI-generated summary of Item 1 (Business) from the 10-K filed Mar 31, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q3 2026| Largest holders | Reported value |
|---|---|
| Opaleye Management Inc | $29.7M |
| AWM Investment Company Inc | $15.0M |
| Cable Car Capital LP | $12.4M |
| Solas Capital Management LLC | $12.3M |
| Ikarian Capital LLC | $6.3M |
Annual results · 10-K
Fiscal 2025- Revenue
- $10.2M
- Net loss
- -$20.7M
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
2 funds| Fund | Value | % of fund |
|---|---|---|
| Fidelity Nasdaq Composite Index Fund | $132.6K | < 0.01% |
| Avantis U.S. Small Cap Equity ETF AVSC | $38.9K | < 0.01% |
2 funds reported holding $171.5K in total on their latest public Form N-PORT reports, the most recent dated August 2026. Security record
Securities
Insider trades · Form 4
Latest filings
- Caren Deardorf 2026-11-13 Award
- Opaleye Management Inc. 2026-10-26 Buy
- Opaleye Management Inc. 2026-10-19 Buy
- Opaleye Management Inc. 2026-10-02 Buy
- Opaleye Management Inc. 2026-09-28 Buy
5%+ holders · 13D/G
6 filers| Filer | % of class | Filed |
|---|---|---|
| Solas Capital Management LLC 13G | 6.3% | 2026-11-16 |
| Manchester Management Company LLC 13G | 7.4% | 2026-09-23 |
| Opaleye Management Inc 13G | 14.2% | 2026-07-24 |
| Funicular Funds LP 13G | 5.1% | 2026-02-19 |
| AWM Investment Company Inc 13G | 9.9% | 2026-02-13 |
| BESSER JAMES E 13G | 6.2% | 2025-01-31 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.